BDRX (Biodexa Pharmaceuticals) Accumulated Depreciation: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
24 GF Score
Price $0.67
! 1 Warning Sign
View Full Analysis

What is Biodexa Pharmaceuticals Accumulated Depreciation?

Biodexa Pharmaceuticals BDRX -2.18% 24 Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus rates BDRX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Biodexa Pharmaceuticals's quarterly accumulated depreciation declined from Jun. 2025 ($ Mil) to Dec. 2025 ($-1.14 Mil) but then increased from Dec. 2025 ($-1.14 Mil) to Jun. 2026 ($ Mil).

Biodexa Pharmaceuticals's annual accumulated depreciation declined from Dec. 2023 ($-2.20 Mil) to Dec. 2024 ($-1.53 Mil) but then stayed the same from Dec. 2024 ($-1.53 Mil) to Dec. 2025 ($-1.14 Mil).

Biodexa Pharmaceuticals Accumulated Depreciation Related Terms

Biodexa Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Accumulated Depreciation Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.22 -1.96 -2.20 -1.53 -1.14

Biodexa Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.53 - -1.14 -
BDRX
24GF Score
Biodexa Pharmaceuticals PLC BDRX
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $ Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Accumulated Depreciation of $ Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Accumulated Depreciation too high?
Biodexa Pharmaceuticals' current Accumulated Depreciation is $ Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Accumulated Depreciation compare to ZVSA and AGTX?
Biodexa Pharmaceuticals' Accumulated Depreciation of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Accumulated Depreciation is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Accumulated Depreciation of $ Mil. The current Accumulated Depreciation is $ Mil. Biodexa Pharmaceuticals' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company based in the United Kingdom that develops therapies for diseases with unmet medical needs, with a focus on oncology and rare diseases. Its pipeline includes candidates for familial adenomatous polyposis, non-muscle invasive bladder cancer, type 1 diabetes, and rare or orphan brain cancers. The company's lead programs include eRapa, an oral rapamycin formulation being developed for familial adenomatous polyposis, and MTX-101, a targeted therapy for rare brain cancers. Biodexa also develops drug delivery technologies designed to improve the administration and targeting of existing medicines. As a clinical-stage company, it does not yet generate substantial product revenue; its operations are funded primarily through equity financings, partnerships, and licensing arrangements. Its activities span preclinical research and clinical trials conducted in the United Kingdom and internationally, with the goal of advancing candidates toward regulatory approval and commercialization.
24GF Score

Get the complete analysis for BDRX

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price